NO328048B1 - Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom - Google Patents

Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom Download PDF

Info

Publication number: NO328048B1
Authority: NO; Norway
Prior art keywords: taxane; pharmaceutically acceptable; tumor; warm; human
Prior art date: 2001-11-08

Application number

NO20042365A

Other languages

English (en)

Norwegian (no)

Other versions

NO20042365L (no

Inventor

Stephen Robert Wedge

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-08

Filing date

2004-06-07

Publication date

2009-11-16

2004-06-07 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-06-07 Publication of NO20042365L publication Critical patent/NO20042365L/no

2009-11-16 Publication of NO328048B1 publication Critical patent/NO328048B1/no

Links

UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 title claims description 97
229940123237 Taxane Drugs 0.000 title claims description 71
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims description 70
239000003814 drug Substances 0.000 title claims description 17
238000004519 manufacturing process Methods 0.000 title claims description 14
239000008194 pharmaceutical composition Substances 0.000 title claims description 3
238000011282 treatment Methods 0.000 title description 36
201000010099 disease Diseases 0.000 title description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 7
241001465754 Metazoa Species 0.000 claims description 56
206010028980 Neoplasm Diseases 0.000 claims description 54
230000000694 effects Effects 0.000 claims description 43
150000003839 salts Chemical class 0.000 claims description 38
230000005865 ionizing radiation Effects 0.000 claims description 35
229930012538 Paclitaxel Natural products 0.000 claims description 26
229960001592 paclitaxel Drugs 0.000 claims description 26
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 26
230000001772 anti-angiogenic effect Effects 0.000 claims description 17
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 13
229960003668 docetaxel Drugs 0.000 claims description 13
230000001093 anti-cancer Effects 0.000 claims description 12
210000004072 lung Anatomy 0.000 claims description 12
230000000259 anti-tumor effect Effects 0.000 claims description 11
230000002137 anti-vascular effect Effects 0.000 claims description 9
230000000306 recurrent effect Effects 0.000 claims description 9
239000002552 dosage form Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000000654 additive Substances 0.000 claims description 6
210000000481 breast Anatomy 0.000 claims description 6
230000002792 vascular Effects 0.000 claims description 6
230000000996 additive effect Effects 0.000 claims description 5
210000002307 prostate Anatomy 0.000 claims description 5
210000003491 skin Anatomy 0.000 claims description 5
201000006385 lung benign neoplasm Diseases 0.000 claims description 4
208000020816 lung neoplasm Diseases 0.000 claims description 4
238000004806 packaging method and process Methods 0.000 claims description 2
210000000936 intestine Anatomy 0.000 claims 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 76
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
239000000243 solution Substances 0.000 description 32
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
239000007787 solid Substances 0.000 description 22
239000000203 mixture Substances 0.000 description 21
238000001914 filtration Methods 0.000 description 20
150000001875 compounds Chemical class 0.000 description 19
238000000034 method Methods 0.000 description 17
238000011284 combination treatment Methods 0.000 description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
201000011510 cancer Diseases 0.000 description 14
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
238000003756 stirring Methods 0.000 description 12
239000000725 suspension Substances 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
239000012044 organic layer Substances 0.000 description 11
239000002244 precipitate Substances 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 10
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
239000003039 volatile agent Substances 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000012267 brine Substances 0.000 description 9
238000002648 combination therapy Methods 0.000 description 9
238000001704 evaporation Methods 0.000 description 9
230000008020 evaporation Effects 0.000 description 9
230000004044 response Effects 0.000 description 9
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
239000003208 petroleum Substances 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
230000008569 process Effects 0.000 description 8
238000001959 radiotherapy Methods 0.000 description 8
230000012010 growth Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
206010061818 Disease progression Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
230000005750 disease progression Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
-1 alkali metal salt Chemical class 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
239000012458 free base Substances 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
239000010410 layer Substances 0.000 description 5
KVBQCJXMSFJOFP-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC3CCN(C)CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F KVBQCJXMSFJOFP-UHFFFAOYSA-N 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000007858 starting material Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
230000008728 vascular permeability Effects 0.000 description 5
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
238000001816 cooling Methods 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
229910000041 hydrogen chloride Inorganic materials 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
230000005855 radiation Effects 0.000 description 4
108091008598 receptor tyrosine kinases Proteins 0.000 description 4
102000027426 receptor tyrosine kinases Human genes 0.000 description 4
238000010992 reflux Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 4
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
JXVISOHOJNTGTD-UHFFFAOYSA-N 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-1h-quinazolin-4-one Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC1CCN(C)CC1 JXVISOHOJNTGTD-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
KWCVUWUJDCWGGM-UHFFFAOYSA-N (6-methoxy-4-oxo-7-phenylmethoxyquinazolin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound COC1=CC(C(N(COC(=O)C(C)(C)C)C=N2)=O)=C2C=C1OCC1=CC=CC=C1 KWCVUWUJDCWGGM-UHFFFAOYSA-N 0.000 description 2
NZXRRNLMXLRCAF-UHFFFAOYSA-N (7-hydroxy-6-methoxy-4-oxoquinazolin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound N1=CN(COC(=O)C(C)(C)C)C(=O)C2=C1C=C(O)C(OC)=C2 NZXRRNLMXLRCAF-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
XIHOMGRMQWNHHB-UHFFFAOYSA-N 4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F XIHOMGRMQWNHHB-UHFFFAOYSA-N 0.000 description 2
GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 2
XAVZTXQALXOZJS-UHFFFAOYSA-N 4-chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCC1CCN(C)CC1 XAVZTXQALXOZJS-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
MWAYRGBWOVHDDZ-UHFFFAOYSA-N Ethyl vanillate Chemical compound CCOC(=O)C1=CC=C(O)C(OC)=C1 MWAYRGBWOVHDDZ-UHFFFAOYSA-N 0.000 description 2
208000012766 Growth delay Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
208000034038 Pathologic Neovascularization Diseases 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
UDQOUIKKIADMCY-UHFFFAOYSA-N [6-methoxy-4-oxo-7-(piperidin-4-ylmethoxy)quinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound COC1=CC(C(N(COC(=O)C(C)(C)C)C=N2)=O)=C2C=C1OCC1CCNCC1 UDQOUIKKIADMCY-UHFFFAOYSA-N 0.000 description 2
NUZXMXNVVMJLOP-UHFFFAOYSA-N [6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound COC1=CC(C(N(COC(=O)C(C)(C)C)C=N2)=O)=C2C=C1OCC1CCN(C)CC1 NUZXMXNVVMJLOP-UHFFFAOYSA-N 0.000 description 2
XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
LRHBZJAIQBBNFI-UHFFFAOYSA-N ethyl 3-methoxy-4-[(1-methylpiperidin-4-yl)methoxy]benzoate Chemical compound COC1=CC(C(=O)OCC)=CC=C1OCC1CCN(C)CC1 LRHBZJAIQBBNFI-UHFFFAOYSA-N 0.000 description 2
YKLVXLQPUAUIGF-UHFFFAOYSA-N ethyl 5-methoxy-4-[(1-methylpiperidin-4-yl)methoxy]-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OCC)=CC(OC)=C1OCC1CCN(C)CC1 YKLVXLQPUAUIGF-UHFFFAOYSA-N 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
201000011066 hemangioma Diseases 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
108010082117 matrigel Proteins 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
HTCPERSEGREUFC-UHFFFAOYSA-N n-desmethyl vandetanib Chemical compound N1=CN=C2C=C(OCC3CCNCC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F HTCPERSEGREUFC-UHFFFAOYSA-N 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
CTEDVGRUGMPBHE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)CC1 CTEDVGRUGMPBHE-UHFFFAOYSA-N 0.000 description 2
DARTVAOOTJKHQW-UHFFFAOYSA-N tert-butyl 4-[(4-methylphenyl)sulfonyloxymethyl]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1CCN(C(=O)OC(C)(C)C)CC1 DARTVAOOTJKHQW-UHFFFAOYSA-N 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
NSNFLSUFJFOYIJ-UHFFFAOYSA-N 4-chloro-6-methoxy-7-phenylmethoxyquinazoline;hydrochloride Chemical compound Cl.COC1=CC2=C(Cl)N=CN=C2C=C1OCC1=CC=CC=C1 NSNFLSUFJFOYIJ-UHFFFAOYSA-N 0.000 description 1
ZCUFFSHMOAEEIL-UHFFFAOYSA-N 6-methoxy-7-phenylmethoxy-1h-quinazolin-4-one Chemical compound COC1=CC2=C(O)N=CN=C2C=C1OCC1=CC=CC=C1 ZCUFFSHMOAEEIL-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010051113 Arterial restenosis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
206010025282 Lymphoedema Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027514 Metrorrhagia Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
230000004075 alteration Effects 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
229960001776 edrecolomab Drugs 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
TVBGZCDJLZJQOA-UHFFFAOYSA-N ethyl 2-amino-5-methoxy-4-[(1-methylpiperidin-4-yl)methoxy]benzoate Chemical compound C1=C(N)C(C(=O)OCC)=CC(OC)=C1OCC1CCN(C)CC1 TVBGZCDJLZJQOA-UHFFFAOYSA-N 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
238000001325 log-rank test Methods 0.000 description 1
208000002502 lymphedema Diseases 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
FZMIEQCEGTVFBZ-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=CN=C2C=C(OCC3CCN(C)CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F FZMIEQCEGTVFBZ-UHFFFAOYSA-N 0.000 description 1
CAJIOLKERBQYCQ-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-6-methoxy-7-phenylmethoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F CAJIOLKERBQYCQ-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
210000001210 retinal vessel Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
OHTLVKDBACKIFE-UHFFFAOYSA-N tert-butyl 4-[(4-ethoxycarbonyl-2-methoxyphenoxy)methyl]piperidine-1-carboxylate Chemical compound COC1=CC(C(=O)OCC)=CC=C1OCC1CCN(C(=O)OC(C)(C)C)CC1 OHTLVKDBACKIFE-UHFFFAOYSA-N 0.000 description 1
DJQLEEANCWENKG-UHFFFAOYSA-N tert-butyl 4-[[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]piperidine-1-carboxylate Chemical compound N1=CN=C2C=C(OCC3CCN(CC3)C(=O)OC(C)(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F DJQLEEANCWENKG-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000004066 vascular targeting agent Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20042365A 2001-11-08 2004-06-07 Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom NO328048B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0126879.6A GB0126879D0 (en)	2001-11-08	2001-11-08	Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en)	2001-11-08	2002-11-06	Combination therapy comprising zd6474 and a taxane

Publications (2)

Publication Number	Publication Date
NO20042365L NO20042365L (no)	2004-06-07
NO328048B1 true NO328048B1 (no)	2009-11-16

Family

ID=9925430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042365A NO328048B1 (no)	2001-11-08	2004-06-07	Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom

Country Status (22)

Country	Link
US (2)	US20050043395A1 (es)
EP (1)	EP1446124B1 (es)
JP (1)	JP4694127B2 (es)
KR (1)	KR100959607B1 (es)
CN (1)	CN1298328C (es)
AR (1)	AR037346A1 (es)
AT (1)	ATE335488T1 (es)
AU (1)	AU2002337382B2 (es)
BR (1)	BR0213906A (es)
CA (1)	CA2464758C (es)
CY (1)	CY1106259T1 (es)
DE (1)	DE60213845T2 (es)
DK (1)	DK1446124T3 (es)
ES (1)	ES2269769T3 (es)
GB (1)	GB0126879D0 (es)
IL (2)	IL161744A0 (es)
MX (1)	MXPA04004355A (es)
NO (1)	NO328048B1 (es)
NZ (1)	NZ532525A (es)
PT (1)	PT1446124E (es)
WO (1)	WO2003039551A1 (es)
ZA (1)	ZA200403455B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1676845B1 (en)	1999-11-05	2008-06-11	AstraZeneca AB	New quinazoline derivatives
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
DK1274692T3 (da)	2000-04-07	2006-10-30	Astrazeneca Ab	Quinazolinforbindelser
US7268230B2 (en) *	2002-02-01	2007-09-11	Astrazeneca Ab	Quinazoline compounds
TWI324597B (en) *	2002-03-28	2010-05-11	Astrazeneca Ab	Quinazoline derivatives
GB0218526D0 (en) *	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0223380D0 (en) *	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
ES2300619T3 (es)	2002-11-04	2008-06-16	Astrazeneca Ab	Derivados de quinolina como inhibidores de src tirosina quinasa.
WO2004071397A2 (en) *	2003-02-13	2004-08-26	Astrazeneca Ab	Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
ATE478671T1 (de) *	2003-07-10	2010-09-15	Astrazeneca Ab	Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
CA2545054A1 (en) *	2003-11-14	2005-06-02	Pharma Mar, S.A.	Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0411378D0 (en) *	2004-05-21	2004-06-23	Astrazeneca Ab	Pharmaceutical compositions
JP2008504292A (ja) *	2004-06-24	2008-02-14	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	免疫増強用の化合物
JP2008514577A (ja) *	2004-09-27	2008-05-08	アストラゼネカアクチボラグ	Ｚｄ６４７４及びイマチニブを含んでなる組合せ
GB0424339D0 (en) *	2004-11-03	2004-12-08	Astrazeneca Ab	Combination therapy
GB0519879D0 (en)	2005-09-30	2005-11-09	Astrazeneca Ab	Chemical process
JP5167144B2 (ja) *	2005-12-22	2013-03-21	アストラゼネカアクチボラグ	併用療法
JP2009538317A (ja) *	2006-05-26	2009-11-05	バイエルヘルスケアリミティドライアビリティカンパニー	癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
WO2008037996A1 (en) *	2006-09-29	2008-04-03	Astrazeneca Ab	Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) *	2007-02-12	2008-08-14	Ballard Ebbin C	Inserts for engine exhaust systems
BRPI0912170A2 (pt) *	2008-05-13	2015-10-13	Astrazeneca Ab	composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
WO2010061208A2 (en) *	2008-11-03	2010-06-03	Astrazeneca Ab	Therapeutic treatment 555
CN106397401B (zh) *	2016-08-30	2018-11-13	山东罗欣药业集团股份有限公司	一种抗癌药物的晶体化合物及其制备方法
CN106478598B (zh) *	2016-08-30	2018-11-13	山东罗欣药业集团股份有限公司	一种凡德他尼水合物晶体及其制备方法
AU2021409515A1 (en) *	2020-12-22	2023-07-06	Hanmi Pharmaceutical Co., Ltd.	Novel quinazoline derivatives as SOS1 inhibitors and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EP0910382B1 (en) *	1996-04-26	2003-06-11	Magainin Pharmaceuticals Inc.	Squalamine in combination with other anti-cancer agents for treating tumors
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9727524D0 (en) *	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Synergistic antitumor composition containing a biologically active ureido compound
WO2000050059A1 (en) *	1999-02-24	2000-08-31	The Uab Research Foundation	Taxane derivatives for targeted therapy of cancer
HK1045700B (zh) *	1999-04-28	2007-07-27	德克萨斯大学董事会	用於通过选择性抑制vegf来治疗癌症的组合物和方法
EP1676845B1 (en) *	1999-11-05	2008-06-11	AstraZeneca AB	New quinazoline derivatives
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
AU2003249000B2 (en) *	2002-08-09	2007-04-05	Astrazeneca Ab	Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) *	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0223380D0 (en) *	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
WO2004071397A2 (en) *	2003-02-13	2004-08-26	Astrazeneca Ab	Combination therapy of zd6474 with 5-fu or/and cpt-11
ATE478671T1 (de) *	2003-07-10	2010-09-15	Astrazeneca Ab	Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
JP2008514577A (ja) *	2004-09-27	2008-05-08	アストラゼネカアクチボラグ	Ｚｄ６４７４及びイマチニブを含んでなる組合せ
GB0424339D0 (en) *	2004-11-03	2004-12-08	Astrazeneca Ab	Combination therapy
JP5167144B2 (ja) *	2005-12-22	2013-03-21	アストラゼネカアクチボラグ	併用療法
WO2008037996A1 (en) *	2006-09-29	2008-04-03	Astrazeneca Ab	Combination of zd6474 and bevacizumab for cancer therapy

2001
- 2001-11-08 GB GBGB0126879.6A patent/GB0126879D0/en not_active Ceased
2002
- 2002-11-06 IL IL16174402A patent/IL161744A0/xx unknown
- 2002-11-06 MX MXPA04004355A patent/MXPA04004355A/es active IP Right Grant
- 2002-11-06 AU AU2002337382A patent/AU2002337382B2/en not_active Ceased
- 2002-11-06 JP JP2003541842A patent/JP4694127B2/ja not_active Expired - Fee Related
- 2002-11-06 DK DK02772624T patent/DK1446124T3/da active
- 2002-11-06 ES ES02772624T patent/ES2269769T3/es not_active Expired - Lifetime
- 2002-11-06 AT AT02772624T patent/ATE335488T1/de active
- 2002-11-06 DE DE60213845T patent/DE60213845T2/de not_active Expired - Lifetime
- 2002-11-06 PT PT02772624T patent/PT1446124E/pt unknown
- 2002-11-06 NZ NZ532525A patent/NZ532525A/en not_active IP Right Cessation
- 2002-11-06 US US10/494,704 patent/US20050043395A1/en not_active Abandoned
- 2002-11-06 BR BR0213906-5A patent/BR0213906A/pt not_active IP Right Cessation
- 2002-11-06 WO PCT/GB2002/005021 patent/WO2003039551A1/en not_active Ceased
- 2002-11-06 KR KR1020047007020A patent/KR100959607B1/ko not_active Expired - Fee Related
- 2002-11-06 CA CA2464758A patent/CA2464758C/en not_active Expired - Fee Related
- 2002-11-06 CN CNB028267958A patent/CN1298328C/zh not_active Expired - Fee Related
- 2002-11-06 EP EP02772624A patent/EP1446124B1/en not_active Expired - Lifetime
- 2002-11-08 AR ARP020104292A patent/AR037346A1/es not_active Application Discontinuation
2004
- 2004-05-03 IL IL161744A patent/IL161744A/en not_active IP Right Cessation
- 2004-05-06 ZA ZA200403455A patent/ZA200403455B/en unknown
- 2004-06-07 NO NO20042365A patent/NO328048B1/no not_active IP Right Cessation
2006
- 2006-11-09 CY CY20061101619T patent/CY1106259T1/el unknown
2011
- 2011-11-07 US US13/290,730 patent/US20120252827A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20120252827A1 (en)	2012-10-04
NZ532525A (en)	2006-11-30
JP4694127B2 (ja)	2011-06-08
MXPA04004355A (es)	2004-08-11
US20050043395A1 (en)	2005-02-24
IL161744A0 (en)	2005-11-20
PT1446124E (pt)	2006-12-29
DK1446124T3 (da)	2006-11-13
DE60213845D1 (de)	2006-09-21
AR037346A1 (es)	2004-11-03
HK1068546A1 (en)	2005-04-29
NO20042365L (no)	2004-06-07
WO2003039551A1 (en)	2003-05-15
DE60213845T2 (de)	2007-03-29
CY1106259T1 (el)	2011-06-08
BR0213906A (pt)	2004-08-31
EP1446124A1 (en)	2004-08-18
KR100959607B1 (ko)	2010-05-27
CN1298328C (zh)	2007-02-07
AU2002337382B2 (en)	2008-06-12
EP1446124B1 (en)	2006-08-09
KR20050043779A (ko)	2005-05-11
ZA200403455B (en)	2005-08-29
CA2464758A1 (en)	2003-05-15
CA2464758C (en)	2010-09-28
GB0126879D0 (en)	2002-01-02
ES2269769T3 (es)	2007-04-01
CN1612738A (zh)	2005-05-04
JP2005511597A (ja)	2005-04-28
ATE335488T1 (de)	2006-09-15
IL161744A (en)	2012-01-31

Publication	Publication Date	Title
NO328048B1 (no)	2009-11-16	Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom
JP5563950B2 (ja)	2014-07-30	組合せ療法
AU2002337382A1 (en)	2003-07-24	Combination therapy comprising ZD6474 and a taxane
US20100029673A1 (en)	2010-02-04	Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
US20050222183A1 (en)	2005-10-06	Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
ES2364030T3 (es)	2011-08-23	Terapia de combinación de zd6474 con 5-fu y/o cpt-11.
US20240024324A1 (en)	2024-01-25	Kinase inhibitor combinations for cancer treatment
HK1068546B (en)	2007-01-05	Combination therapy comprising zd6474 and a taxane

Legal Events

Date	Code	Title	Description
2014-06-23	MM1K	Lapsed by not paying the annual fees